Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients- a Randomized Study; a Step Towards Tailored PRRT
Latest Information Update: 15 May 2023
At a glance
- Drugs Lu-177 octreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- Acronyms DOBATOC
Most Recent Events
- 10 May 2023 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
- 10 May 2023 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.
- 25 Oct 2019 New trial record